International Journal of Clinical Pharmacy

, Volume 35, Issue 4, pp 613–620 | Cite as

Antihypertensive use before and after initiation of fixed-dose combination products in Australia: a retrospective study

  • Svetla Gadzhanova
  • Jenni Ilomäki
  • Elizabeth E. Roughead
Research Article

Abstract

Background National guidelines in Australia advise that patients should be stabilised on both individual antihypertensive medicines before initiating a fixed-dose combination (FDC) product. Objective The aim of this study was to examine the antihypertensive medicines use before and after initiation of four antihypertensive FDC products recently listed under the Australian Pharmaceutical Benefits Scheme—olmesartan or valsartan with hydrochlorothiazide, valsartan with amlodipine and ramipril with felodipine. Setting Australian veteran population Methods This was a retrospective cohort study using Australian Government Department of Veterans’ Affairs pharmacy claims data. Subjects initiating a FDC between 2008 and 2010 were included. Their antihypertensive medicine use was investigated in the 12-months prior to and post FDC product initiation. Main outcome measure Proportions of FDC initiators dispensed one or both of the individual medicines, or who had antihypertensive medicines other than the individual ones were assessed for the 12 months prior to initiation. For the post history, proportions of patients who continued the FDC as a sole therapy, had other antihypertensives co-administered with FDC, or ceased the FDC were established. Results 2,513 participants initiated one of the four FDC products in the study period. Immediately prior to FDC initiation, below 1 % had both individual medicines, 29 % had one of the individual medicines, 58 % had antihypertensive medicines other than the individual ones, and 12 % had no antihypertensive therapy. At 12 months post initiation, 25 % of the FDC initiators continued it as a sole treatment, 35 % required an additional antihypertensive medicine in addition to FDC product, and 40 % ceased the FDC. Conclusion A minority of patients initiated combination products after being stabilised on both individual medicines. Significant number had no prior history of antihypertensive use. One-third of FDC initiators still required additional antihypertensive medication concurrently with the FDC product at 12 months post initiation.

Keywords

Aged Antihypertensive agents Australia Combination therapy Drug utilisation Elderly epidemiology Veterans 

References

  1. 1.
    Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4:393–404.CrossRefGoogle Scholar
  2. 2.
    Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290–300.PubMedCrossRefGoogle Scholar
  3. 3.
    Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J (Clin Res Ed). 2003;326:1427.CrossRefGoogle Scholar
  4. 4.
    Struijker-Boudier HA, Ambrosioni E, Holzgreve H, Laurent S, Mancia G, Ruilope LM, et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity–mortality trials? Int J Clin Pract. 2007;61:1592–602.PubMedCrossRefGoogle Scholar
  5. 5.
    Simons LA, Ortiz M, Calcino G. Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006–2010. Med J Aust. 2011;195:134–7.PubMedGoogle Scholar
  6. 6.
    Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399–407.PubMedCrossRefGoogle Scholar
  7. 7.
    Horn FE, Mandryk JA, Mackson JM, Wutzke SE, Weekes LM, Hyndman RJ. Measurement of changes in antihypertensive drug utilisation following primary care educational interventions. Pharmacoepidemiol Drug Saf. 2007;16:297–308.PubMedCrossRefGoogle Scholar
  8. 8.
    Byrd JB, Zeng C, Tavel HM, Magid DJ, O’Connor PJ, Margolis KL, et al. Combination therapy as initial treatment for newly diagnosed hypertension. Am Heart J. 2011;162:340–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Walker RL, Chen G, Campbell NR, McAlister FA, Quan H, Tu K, et al. Canadian provincial trends in antihypertensive drug prescriptions between 1996 and 2006. Can J Cardiol. 2011;27:461–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens. 2009;27:2121–58.PubMedCrossRefGoogle Scholar
  11. 11.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, et al. The 2011 canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2011;27:415–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Rosenthal T, Gavras I. Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis. 2006;48:416–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2007;65:795–6.CrossRefGoogle Scholar
  15. 15.
    Kamaruzzaman S, Watt H, Carson C, Ebrahim S. The association between orthostatic hypotension and medication use in the British women’s heart and health study. Age Ageing. 2010;39:51–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30:173–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Gangavati A, Hajjar I, Quach L, Jones RN, Kiely DK, Gagnon P, et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population: the maintenance of balance, independent living, intellect, and zest in the elderly of Boston study. J Am Geriatr Soc. 2011;59:383–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Deandrea S, Lucenteforte E, Bravi F, Foschi R, La Vecchia C, Negri E. Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology. 2010;21:658–68.PubMedCrossRefGoogle Scholar
  19. 19.
    Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172:1739–44.PubMedGoogle Scholar
  20. 20.
    Allan LM, Ballard CG, Rowan EN, Kenny RA. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS ONE. 2009;5:e5521.CrossRefGoogle Scholar
  21. 21.
    Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J. 2010;31:85–91.PubMedCrossRefGoogle Scholar
  22. 22.
    National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated December 2010. National Heart Foundation of Australia; 2010.Google Scholar
  23. 23.
    National Prescribing Service. Managing hypertension as a cardiovascular risk factor. Strawberry Hills: National Prescribing Service Limited; 2007.Google Scholar
  24. 24.
    National Prescribing Service. Olmesartan medoxomil (Olmetec) monotherapy or in combination with hydrochlorothiazide (Olmetec Plus) for hypertension: National Prescribing Service Limited; 2007.Google Scholar
  25. 25.
    National Prescribing Service. Be aware of dose ranges for new ramipril with felodipine combination (Triasyn). National Prescribing Service Limited; 2007.Google Scholar
  26. 26.
    National Prescribing Service. Valsartan (Diovan) and combinations with hydrochlorothiazide (Co-Diovan) or amlodipine (Exforge). National Prescribing Service Limited; 2009.Google Scholar
  27. 27.
    Australian Prescriber. New combinations enalapril maleate/hydrochlorothiazide. Australian Prescriber. 2001;24: p 203.Google Scholar
  28. 28.
    Australian Government Department of Health and Ageing. Formulary allocations 1 Oct 2012. Canberra: Department of Health and Ageing; 2012 [cited 2012 Oct 29]; Available from: http://www.pbs.gov.au/info/industry/pricing/pbs-items/formulary-allocations.
  29. 29.
    Lloyd J, Anderson P. Australian institute of health and welfare. Veterans’ use of health services. Canberra: AIHW; 2008.Google Scholar
  30. 30.
    Australian Government Department of Veterans’ Affairs. Treatment population statistics December 2011. Canberra: Australian Government Department of Veterans’ Affairs; 2011.Google Scholar
  31. 31.
    WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification system. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. 2012 [cited 2012 Oct 29]. Available from: http://www.whocc.no/atcddd/.

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Svetla Gadzhanova
    • 1
  • Jenni Ilomäki
    • 1
  • Elizabeth E. Roughead
    • 1
  1. 1.Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical SciencesUniversity of South AustraliaAdelaideAustralia

Personalised recommendations